Is Gilead's Bump Legit? 9/24/12

There are a lot of economic numbers coming out this week, and the reports could give us a good idea of how the U.S. economy is really doing. Gilead had a strong week after a big Wall Street recommendation, but is the company’s boost something that is sustainable, or will you regret jumping on the wagon?

Plus, Marek mentions some more drugs that are up for approval before the end of the year.

If you have any questions for Marek, he can be contacted through Twitter at @MarekFuchs.

Watch past Wall Street Wrap Up videos here.

Marek Fuchs was a stockbroker for Shearson Lehman Brothers before becoming a journalist who wrote The New York Times' "County Lines" column for six years. Marek speaks regularly on business and journalism issues at venues ranging from annual meetings of the Society of American Business Editors and Writers to PBS to National Public Radio. His last book, A Cold-Blooded Business, was called "riveting" by Kirkus Reviews and next book, Local Heroes: Portraits of American Volunteer Firefighters is due out in 2012. He is on the writing faculty at Sarah Lawrence College. When Marek is not writing, teaching or filming videos, he serves as a volunteer firefighter.